Viewing Study NCT02580305

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:18 AM
Ignite Modification Date: 2026-02-13 @ 10:52 AM
Study NCT ID: NCT02580305
Status: COMPLETED
Last Update Posted: 2023-06-09
First Post: 2015-10-17
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
Sponsor: Suven Life Sciences Limited
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Alzheimer's Disease View
Keywords:

Keywords

Keyword Brief Keyword Text View
None SUVN-502 View
None 5-HT6 View
None Phase 2 View
None Cognition View
None Donepezil View
None Memantine View
None Alzheimer's Disease View
None Triple Combination View
None Proof of Concept (POC) View